(Q34851219)

4 August 2017

Canagliflozin: effects in overweight and obese subjects without diabetes mellitus (English)

1 reference

4 August 2017

0 references

Harold E Bays

1

1 reference

4 August 2017

Richard Weinstein

series ordinal

2

1 reference

4 August 2017

Gordon Law

series ordinal

3

1 reference

4 August 2017

William Canovatchel

series ordinal

4

1 reference

4 August 2017

language of work or name

1 reference

9 December 2013

1 reference

4 August 2017

1 reference

4 August 2017

22

1 reference

4 August 2017

4

1 reference

4 August 2017

1042-1049

1 reference

Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Adiposopathy is "sick fat" a cardiovascular disease?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

SLC2A9 is a high-capacity urate transporter in humans

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4285787

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

8 July 2018

1 reference

Development of a brief measure to assess quality of life in obesity.

21 January 2018

1 reference

Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample

21 January 2018

1 reference

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

21 January 2018

1 reference

Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women

21 January 2018

1 reference

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

21 January 2018

1 reference

From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus

21 January 2018

1 reference

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24227660

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24227660

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/OBY.20663

1 reference

4 August 2017

1 reference

4 August 2017

1 reference